[Form 4] SkyWater Technology, Inc Insider Trading Activity
SkyWater Technology (SKYT) CFO Steve Manko executed and disclosed option exercise and share sales under a Rule 10b5-1 plan on 09/26/2025. He exercised 19,544 options with a $14 exercise price, resulting in acquisition of 19,544 common shares. On the same date he sold 60,829 shares at a weighted-average price of $17.40 (individual sale prices ranged from $17.25 to $18.07). The filing reports beneficial ownership of 387,951 shares after the option exercise and 327,122 shares after the sales. Both transactions were effected pursuant to a Rule 10b5-1 trading plan entered March 14, 2025. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.
- Transactions executed under a Rule 10b5-1 plan, indicating pre-established, compliant trading arrangements
- Clear disclosure of quantities and weighted-average sale price (sales at $17.25–$18.07; weighted average $17.40)
- Form 4 includes required procedural elements such as attorney-in-fact signature and exercise/sale details
- CFO reduced beneficial ownership by 60,829 shares (from 387,951 to 327,122) which may be viewed negatively by some investors
- Large insider sale on a single date could attract market attention despite being pre-planned
Insights
TL;DR: Insider exercised options and sold shares under a pre-established 10b5-1 plan; disclosure is routine and compliant.
The transactions combine a stock-option exercise and a subsequent open-market sale executed on 09/26/2025 under a Rule 10b5-1 plan dated March 14, 2025. The exercise converted 19,544 options at $14 into the same number of shares, increasing reported holdings to 387,951, followed by sales of 60,829 shares at a weighted average of $17.40 reducing holdings to 327,122. From an analytical perspective this represents a liquidity event by the CFO executed under an established plan, which reduces insider stake but follows recognized compliance mechanisms and provides clear price and quantity disclosure.
TL;DR: Transactions follow formal Rule 10b5-1 procedures, indicating pre-planned disposition rather than opportunistic trading.
The filing explicitly states both the option exercise and the share sale were effected pursuant to a Rule 10b5-1 trading plan entered March 14, 2025, which supports compliance with insider trading rules. The disclosure includes the weighted-average sale price range and notes option vesting schedule language for the original grant. Signature by an attorney-in-fact is included, meeting procedural requirements. The filing does not report any derivative holdings remaining following the reported exercise.